Deerfield

Deerfield Management Company is a healthcare investment firm launched in 1994. Its public materials describe it as an investor across therapeutics, medical devices, diagnostics, digital health, and healthcare services, investing across the capital structure and at all stages of company development. Deerfield’s contact page lists its New York City office at 345 Park Avenue South in New York, New York, United States.

Deerfield is relevant to the psychedelic ecosystem primarily through its broad therapeutics focus and its ability to back early-stage to later-stage life science companies. While its public website does not identify a dedicated psychedelic program, its investment platform includes drug-development-oriented work and a portfolio spanning early-stage therapeutics, which makes it a plausible investor in adjacent mental-health and neurotherapeutics opportunities.